Immunome Research
Open Access

IP strategies for the biosimilar arena

International Conference and Exhibtion on Antibodies

August 10-11, 2015 Birmingham, UK

Ulrich Storz

Michalski H�¼ttermann & Partner Patentanw�¤lte mbB, Germany

Posters-Accepted Abstracts: Immunome Res

Abstract :

Recent events have shown that lessons learned in generics cannot always be transferred to biosimilars. This applies with respect to technical issues, regulatory issues and IP issues. To cope with this situation, biosimilar companies need, inter alia, a thorough understanding of patent filing strategies related to biologics, as well as of counter measures. Further, because biosimilar companies compete with one another also on a technological level, they should consider developing a patent portfolio to protect proprietary technologies. This presentation explains what biosimilar companies should bear in mind to deal with these challenges.

Biography :

Email: storz@mhpatent.de